Yoney A, Bati Y, Akboru H, Isikli L, Unsal M
Okmeydani Training and Research Hospital, Department of Radiation Oncology, Istanbul, Turkey.
Cancer Radiother. 2010 Jan;14(1):19-23. doi: 10.1016/j.canrad.2009.09.004. Epub 2009 Dec 5.
5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma. However, FU is not well tolerated in a significant proportion of patients. UFT, a fixed combination of the oral FU prodrug tegafur with uracil, is one of the agents used instead of FU in such cases. We retrospectively compared the toxicity, local and distant control and survival rates with FU or oral UFT during concurrent radiotherapy to assess the role of UFT instead of FU.
We conducted a retrospective analysis of survival, disease control and toxicity data in 52 patients treated with postoperative chemoradiation following total or subtotal gastrectomy for gastric adenocarcinoma with either FU or UFT between January 2003 and December 2004.
Median follow-up was 20 months (range: 3-59), median survival time was 23 (+/-6.08) months and 1-3 years overall survival (OS) rates were 64.9-39% for all patients. Compared with the UFT regimen, the incidence of treatment interruption was greater with FU (p=0.023), but no significant differences were seen in local control (p=0.40), distant recurrences (p=0.83) and survival rates (p=0.8657) among patients.
Concurrent UFT with radiotherapy seems to be a more tolerable and an equally effective regimen in the postoperative treatment of gastric adenocarcinoma when compared to FU.
5-氟尿嘧啶（FU）是胃腺癌术后放化疗常用药物。然而，相当一部分患者对FU耐受性不佳。替加氟尿嘧啶（UFT）是口服FU前体药物替加氟与尿嘧啶的固定组合，在此类情况下是用于替代FU的药物之一。我们回顾性比较了同步放疗期间使用FU或口服UFT的毒性、局部和远处控制情况以及生存率，以评估UFT替代FU的作用。
我们对2003年1月至2004年12月间因胃腺癌接受全胃或次全胃切除术后放化疗的52例患者的生存、疾病控制和毒性数据进行了回顾性分析，这些患者使用了FU或UFT。
中位随访时间为20个月（范围：3 - 59个月），中位生存时间为23（±6.08）个月，所有患者1 - 3年总生存率（OS）为64.9% - 39%。与UFT方案相比，FU导致治疗中断的发生率更高（p = 0.023），但患者在局部控制（p = 0.40）、远处复发（p = 0.83）和生存率（p = 0.8657）方面未见显著差异。
与FU相比，同步放疗联合UFT在胃腺癌术后治疗中似乎是一种耐受性更好且同样有效的方案。
Zotero 插件